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Abstract
The Clinic for Special Children (CSC) has integrated biochemical and molecular methods into a rural pediatric practice
serving Old Order Amish and Mennonite (Plain) children. Among the Plain people, we have used single nucleotide
polymorphism (SNP) microarrays to genetically map recessive disorders to large autozygous haplotype blocks
(mean=4.4 Mb) that contain many genes (mean=79). For some, uninformative mapping or large gene lists preclude
disease-gene identification by Sanger sequencing. Seven such conditions were selected for exome sequencing at the Broad
Institute; all had been previously mapped at the CSC using low density SNP microarrays coupled with autozygosity and
linkage analyses. Using between 1 and 5 patient samples per disorder, we identified sequence variants in the known
disease-causing genes SLC6A3 and FLVCR1, and present evidence to strongly support the pathogenicity of variants
identified in TUBGCP6, BRAT1, SNIP1, CRADD, and HARS. Our results reveal the power of coupling new genotyping
technologies to population-specific genetic knowledge and robust clinical data.
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Introduction
The Plain populations of Pennsylvania are descended from
small groups of Swiss immigrants who organized into multiple
endogamous demes that have remained genetically isolated over
the last 12–14 generations [1,2]. Certain recessive disorders are
highly concentrated in Plain sects [3,4]. The overwhelming
majority (.99%) of affected individuals are homozygous for their
respective pathogenic variant, which resides within a relatively
large, homozygous haplotype block. We have exploited this
knowledge to map dozens of recessive conditions using low-
density (i.e. 10,000 and 50,000 marker) single nucleotide
polymorphism (SNP) microarrays with as few as two patients
[5]. This is an efficient, low-cost strategy [2].
The ease of genetic mapping is counterbalanced by the difficulty
of disease gene identification. Shared homozygous blocks among
affected individuals tend to be large (mean 4.4 Mb) and contain
dozens or hundreds of genes [5,6,7,8,9,10,11]. Large gene lists are
significant obstacles, particularly if expression and functional data
provide few clues to prioritize the list. Since 2004, we have
mapped loci for 28 genetic disorders within Amish and Mennonite
demes. For 11 (40%) of these, we could not identify the causative
gene as no pathogenic variants were found after sequencing all
high-priority candidate genes within the mapped interval.
Exome sequencing has recently been shown to expedite disease
gene discovery [12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,
27,28]. In a pilot study to investigate the utility of exome
sequencing, the Clinic for Special Children and the Broad Institute
initiated a collaboration to combine thorough phenotyping,
autozygosity mapping, and exome sequencing. Within 12 months,
we identified pathogenic variants for seven disorders, six of them
novel. To delineate the functional consequences of these variants,
we designed and executed studies of mutant protein expression
and function. This work highlights the extraordinary potential of
next generation technologies for the investigation of monogenic
disease among appropriately selected individuals, families, and
communities. It provides a realistic model for using next
generation sequencing strategies in everyday clinical practice.
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Phenotypes
The phenotypes are summarized in Table 1. Detailed
descriptions of each disorder are presented below.
Infantile Parkinsonism-dystonia syndrome. The pheno-
type and gene defect for infantile parkinsonism-dystonia have been
described elsewhere [29]. Briefly, our patient developed irritability
and feeding difficulties soon after birth. Generalized rigidity and
dystonia developed during early infancy, impeding motor
development, and evolving into severe rigid Parkinsonism by late
childhood. The proband cannot speak or use her hands to
communicate, and it has thus been difficult to assess cognitive
function or thought content. Brain structure is normal. In
cerebrospinal fluid, homovanillic acid (HVA) is elevated, 5-
hydroxyindoleacetic acid (5HIAA) is normal, and the
concentration ratio of HVA to 5HIAA is 6.8–13.2 mol:mol
(normal 1 – 3.7 mol:mol). Treatment with haloperidol,
tetrabenazine, levodopa-carbidopa, trihexyphenidyl, and tyrosine
restriction have been ineffective.
Lethal neonatal rigidity and multifocal seizure
syndrome. Episodic jerking begins in utero. Newborns have
small heads (1.5 to 2 SD below normal for age), overlapping
cranial sutures, small or absent fontanelles, and depressed frontal
bones. Hands are fisted and extreme axial and limb rigidity
prohibit volitional movements and tendon reflexes. Brief focal
jerks of the tongue, face and arms are prominent soon after birth
and occur in a nearly continuous sequence throughout each child’s
short life. Neuroimaging is normal or reveals mild hypoplasia of
the frontal lobes. Electroencephalograms show bilateral medium-
high voltage spikes over temporal and central regions, frequent
multifocal seizures, background slowing, and no posterior rhythm.
Seizures are only partially responsive to anticonvulsants and not
affected by high-dose pyridoxine.
Affected children have stagnant head growth, remain visually
inattentive, do not feed independently, and make no developmen-
tal progress. They have frequent spontaneous apnea and
bradycardia that uniformly culminates in cardiopulmonary arrest
before age 4 months. The brain of a child who died at 4 weeks of
age weighed 382 grams (expected for age 433 +/2 50 g) but was
otherwise normally developed. Primary lesions were localized to
most regions of the corpus striatum and cerebral cortex with
relative sparing of the anterior caudates and parietal lobes. Lesions
consisted of neuronal loss associated with a striking microglial
reaction and proliferation of Alzheimer type 2 astrocytes (Figure 1,
A–C).
Microcephaly with chorioretinopathy. The phenotype was
originally described by Victor McKusick [30]. All patients are born
with microcephaly, a sloping forehead, diminutive anterior
fontanelle, and sutural ridging (Figure 2, A). Head circumference
is more than 4 standard deviations below normal at birth and
remainsso into adulthood(Figure 2, B). Affected neonates transition
well and feed normally. Children walk independently between 14
and 36 months of age and language emerges at an appropriate age
but remains rudimentary. Cognitive impairment ranges from
moderate (adult mental age 8–10 years) to severe (adult mental
age ,6 months); intelligence quotients of two young patients were
60 and 62 (normal 100615). Two of nine patients (22%) have
epilepsy: one started having drop attacks in late childhood and
another developed nocturnal epilepsy as an adult.
Magnetic resonance imaging shows diffuse pachygyria (Figure 2,
C). The cerebral hemispheres are small relative to the cerebellum,
which has a hypoplastic vermis (Figure 2, D). Although myelin
volume appears reduced, it has normal signal quality. The surface
Table 1. Phenotype Summary.
Disease Group OMIM Clinical Synopsis
Infantile parkinsonism-dystonia M – Infantile-onset rigidity, dystonia, or chorea
Dopamine non-responsive Parkinsonism
Progressive frontal lobe degeneration
Lethal neonatal rigidity and seizure syndrome A – In utero myoclonic spasms
Neonatal-onset intractable focal seizures
Congenital rigidity
Dysautonomia (hypothermia, apnea, bradycardia, SIDS)
Mental retardation, non-syndromic M – Delayed language development
Mild-moderate mental retardation
Microcephaly with chorioretinopathy M 251270 Congenital pachygyric microcephaly
Global developmental delay
Chorioretinopathy and retinal detachment
Posterior column ataxia with retinitis pigmentosa M 609033 Impaired propioception
Retinitis pigmentosa
Symptomatic epilepsy and skull dysplasia A – Global developmental delay
Intractable epilepsy
Skull dysplasia
Usher syndrome A – Retinitis pigmentosa
Progressive sensorineural hearing loss
Episodic psychosis
doi:10.1371/journal.pone.0028936.t001
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matched control child (2.75 cm
2 versus 5.61 cm
2).
Visual impairment becomes evident during the first year of life.
The retina and choroid are underdeveloped and have focal defects
that reveal bare sclera. Just posterior to the equator of the eye,
much of the retina has a scalloped appearance that suggests focal
areas of arrested development. The more anterior parts of the
retina, near the periphery and pars plana, have a grayish hue and
Figure 1. Corticobasal degeneration in the brain of an infant who died from a homozygous BRAT1 mutation. (A) Throughout frontal,
occipital and temporal cortex, there is marked neuronal loss, gliosis with astrocytes (arrowheads) and swollen oligodendroglia. The arrow indicates a
perivascular microcalcification (superior frontal gyrus, deep cortex, 106). (B) The anterior hippocampus is smaller than expected and there is neuronal
loss and gliosis in zone CA-1 (Sommer’s sector), demarcated from the CA-2 sector by the dotted line (46). (C)A t6 0 6magnification, the putamen
shows a paucity of neurons, abundant Alzheimer Type 2 astrocytes (arrowhead) and scattered microglial nodules (arrow). Heterologous
overexpression of N-terminal FLAG-tagged human BRAT1 (D) and hBRAT1 c.638_639insA (E) in mouse IMCD3 cells. Wild-type Brat1 localizes to the
nucleus and cytoplasm of mIMCD3 cells. Mutant Brat1 (c.638_639insA) does not localize to the nucleus and instead forms punctate aggregations in
the cytoplasm. Similar results were obtained in hARPE-19 cells (data not shown). (F) RT-PCR demonstrating the stability of overexpressed human
BRAT1 transcripts (,2.6 kb) in hARPE-19 cells. A B-actin amplicon (,450 bp) was used as a loading control on the same gel. (G) Western blot of
lysates from human ARPE-19 cells transiently transfected with wt hBRAT1 displaying FLAG-hBRAT1 fusion protein at ,90 kDa or with hBRAT1
c.638_639insA displaying the truncated FLAG-hBRAT1 mutant fusion protein at ,44.5 kDa (FLAG-tag and linker=3.1 kDa). B-actin was labeled as a
loading control.
doi:10.1371/journal.pone.0028936.g001
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Condensations of vitreous may attach to the retina in transition
regions between scalloped and gray tissue, marking points of
traction for retinal detachment.
Non-syndromic mental retardation. The phenotype is
typical of that described for other forms of non-syndromic
mental retardation. All milestones are mildly delayed and
cognitive function remains significantly impaired, precluding
independent living and self-care. Speech is rudimentary but
articulate. Affected individuals are not autistic.
Posterior column ataxia and retinitis pigmentosa. The
AXPC1 phenotype has been described elsewhere [31]. Tunnel-like
visual loss and photophobia begin early in childhood when
fundoscopy reveals signs of non-spiculated retinitis pigmentosa and
cellophane maculopathy. As vision deteriorates throughout
adolescence, patients might develop posterior subcapsular
cataracts. Motor milestones are slightly delayed (independent
ambulation by 18 months).
Sensory ataxia, wide-based gait, and Rombergism emerge by
age 4. Signs of sensory neuropathy include pan-areflexia, stocking-
glove loss of vibration and position sense, astereognosia,
agraphesthesia, and blunted sensation of applied force (e.g.
accidentally crushing paper cups). Muscle tone, power, and
electromyography are normal. MRI reveals T2 signal hyperinten-
sity running the length of the dorsal spinal cord. Sensory sural
nerve action potentials and H waves are absent. Some patients
develop focal epilepsy marked by interictal focal spike-wave
discharges. Cognitive function is normal.
Symptomatic epilepsy and skull dysplasia. Affected
neonates are hypotonic and feed poorly. Dysmorphic features
that evolve over time include a bulbous nose, wide mouth and
tongue, broad jaw with protuberant angles, short hands, short
tapered fingers, and broad thumbs (Figure 3, A). Affected children
have severe psychomotor delay and do not learn to walk or speak.
Many retain use of their hands to scoot, maneuver a wheelchair,
or gesture. Some children show behavioral responses to language,
but they do not socially engage or follow verbal commands.
Examination typically reveals a subdued child with strabismus,
slow horizontal nystagmus, hypotonia, and weak or absent tendon
reflexes. Magnetic resonance imaging reveals ventriculomegaly,
thin corpus callosum, white matter abnormalities, and an
undulating or ‘‘lumpy’’ skull surface (Figure 3, E). The cortical
ribbon follows the irregular skull contour (Figure 3, E–F).
Multifocal spike-wave discharges from central, occipital, and
Figure 2. Microcephaly and chorioretinopathy due to a homozygous TUBGCP6 mutation. (A) An affected infant has marked microcephaly
(.4SD below normal), a receding forehead, diminutive anterior fontanelle, and sutural ridging. She has cognitive delay and visual impairment but is
socially engaged. (B) Head circumference and length plots for Mennonite microcephaly patients. (C) Brain magnetic resonance imaging (MRI) shows
diffuse pachygyria, normal myelination, and (D) a hypoplastic cerebellar vermis.
doi:10.1371/journal.pone.0028936.g002
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accompanied by focal or generalized seizures that can manifest as
dystonic posturing, drop attacks, myoclonic jerks, or generalized
tonic-clonic events. Multiple intractable seizure types can afflict an
individual patient. Physical anomalies found in some patients
include subglottic stenosis, aortic stenosis, bicuspid aortic valve,
umbilical hernia, and hydrocele.
Usher syndrome. Growth and development are normal
during infancy. Visual impairment becomes evident during early
childhood with the emergence of fine horizontal nystagmus, light
aversion, and optic pallor. As vision deteriorates, fundoscopic exam
reveals marked attenuation of retinal arteries and veins, pigmentary
changes and a cellophane-like reflex that produce ‘‘bull’s eye’’
maculae and diffuse pigmentary stippling of the peripheral retinae,
consistent with retinitis pigmentosa. This constellation suggests a
combination of optic nerve disease, retinal dystrophy, and cone
dysfunction. Patients are typically blind by the second or third
decade of life but the pace of visual deterioration is highly variable.
We do not have auditory data from affected newborns, but
some auditory function is present during infancy and deteriorates
during early childhood; all five evoked auditory waveforms are
absent by age 5. Amplifiers or cochlear implants can partially
restore hearing. Patients have delayed gross motor development,
hyperactive patellar tendon reflexes, mild truncal ataxia, and a
wide-based gait. In contrast, upper limb coordination (allowing for
visual impairment) and reflexes, peripheral nerve function,
strength, tone, and intelligence are normal. Based on the current
classification scheme, this condition is most consistent with the
type III variant of Usher syndrome, which is characterized by
progressive vision and hearing loss during early childhood years.
Infectious illnesses may provoke vivid visual hallucinations (the
Charles Bonnet syndrome). These attacks begin during early
childhood and may be accompanied by nonsensical speech,
inappropriate laughter, repetitive eye blinking, or psychomotor
agitation. In one case, acute psychosis merged into a deep
catatonia that lasted several days. Hallucinations typically respond
to anti-psychotic medications (e.g. haloperidol, thorazine) and are
sometimes associated with transient myopathy (elevated serum
creatine kinase). Rarely, children die suddenly and unexpectedly
during an illness. These are presumably cardiac events, but routine
Figure 3. Symptomatic epilepsy and skull dysplasia due to a homozygous SNIP1 mutation. (A) Two affected brothers presented with
severe psychomotor delay, intractable seizures, bulbous nose, wide mouth and tongue, broad jaw with protuberant angles, short hands, short
tapered fingers, and broad thumbs. (B,C) Brain MRI (B, axial T2; C, coronal T1) MRI showed enlarged ventricles, a thin corpus callosum,
hypomyelination, and an irregular, undulating skull surface. (D) Mouse FLAG-SNIP1 (wt) fusion protein, when transiently overexpressed in mIMCD3
cells, localizes to the nucleus in a punctate pattern consistent with transcriptional complexes. (E) Mouse FLAG-SNIP1 (p.Glu353Gly) localizes to the
nucleus, but with a more aggregated distribution. (F) Top – Reverse-transcriptase PCR from three wild-type mSNIP1-transfected samples and four
c.1058A.G mSNIP1-transfected samples. mSNIP1 amplicon – 400 bp. mGAPDH (loading control) – 1037 bp amplicon. Bottom – Western blot of
lysates from mIMCD3 cells transiently transfected with wt (lanes wt1&2) or c.1058A.G (lanes p.Glu353Gly1&2) mSNIP1 displaying the FLAG-mSNIP
fusion protein at ,48 kDa. The 140-kDa non-specific band was used as a loading control. Data shown are two out of four replicate sets of
transfections.
doi:10.1371/journal.pone.0028936.g003
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normal.
Genetic Mapping
We chose to study 15 patients representing the seven discrete
phenotypes described above (Table 1). All patients were originally
genotyped using 10,000 (10 K) and/or 50,000 (50 K) single
nucleotide polymorphism (SNP) microarrays as previously de-
scribed [5,6,7,8,9,10,11]. Using between 2 and 9 samples, we
genetically mapped five disorders using 10 K SNP arrays; four of
these were localized with ease using multiple affected children from
separate sibships (Figure 4, panels E–H). For two conditions, a shared
homozygous block could only be identified at 50 K SNP resolution
(see below). Shared autozygous blocks were an average of 4.4 Mb
(range 1.6–8.4 Mb) and contained a mean of 79 (range 22–187)
genes. The genetic mapping studies are summarized in Table 2.
For infantile Parkinsonism-dystonia syndrome, the proband was one of
the first patients to be examined at the CSC nearly 20 years ago. A
similarly affected sister died, but a lymphoblastoid cell line was
available for study. No other affected individuals were known in
the Mennonite population. DNA samples were isolated from the
proband, her parents, six unaffected siblings, and her deceased
sister’s cell line. Autozygosity mapping of the two affected
individuals identified a single, large block of homozygosity on
chromosome 6 (Figure 4, panel A, yellow peak). Analysis of the
unaffected siblings excluded this homozygous block, but identified
12 genomic regions greater than 5 Mb in size consistent with
linkage in the family (Figure 4, panel A, red peaks, and panel B).
None of these regions had large homozygous blocks at 10 K SNP
resolution.
Three affected individuals from three separate sibships with
lethal neonatal rigidity and multifocal seizure syndrome were genotyped
Figure 4. Genetic mapping of seven Plain disorders. The results of autozygosity mapping using Affymetrix GeneChip 10 K or 50 K SNP
microarrays are plotted for each disorder. The x-axis depicts chromosomal location on autosomes. Yellow peaks represent the number of contiguous
homozygous SNPs shared by affected individuals and the purple peaks depict location scores. (A) Autozygosity mapping of two affected individuals
identified a single, large block of homozygosity on chromosome 6 (yellow peak). Genotyping of 6 unaffected siblings excluded this homozygous
block, but identified 12 genomic regions greater than 5 Mb in size (red peaks) that were consistent with linkage in the family. (B) List of genomic
regions consistent with linkage in the single nuclear family with infantile parkinsonism-dystonia syndrome. Panels C–H provide mapping plots for the
other 6 disorders. For two disorders (C,D), 50 K microarrays were used after 10 K microarrays failed to unequivocally localize the disease gene. The
other four disorders (E–H) were mapped with 10 K microarrays.
doi:10.1371/journal.pone.0028936.g004
Table 2. Genetic Mapping Summary.
Disease Sample Size Chr SNP Start SNP Stop Size (Mb) Genes
Infantile parkinsonism-dystonia 2 Many – – – –
Lethal neonatal rigidity and seizure
syndrome
3 7 rs2251235 rs765728 1.6 31
Mental retardation, non-syndromic 6 12 rs709228 rs1369822 3.6 46
Microcephaly with chorioretinopathy 6 22 rs2157310 rs7364173 1.8 22
Posterior column ataxia with retinitis
pigmentosa
9 1 rs10494916 rs9308430 4.2 59
Symptomatic epilepsy and skull
dysplasia
6 1 rs2153337 rs2225251 6.6 126
Usher syndrome 3 5 rs2603014 rs325229 8.4 187
doi:10.1371/journal.pone.0028936.t002
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e28936originally with 10 K SNP arrays. No significant shared blocks of
homozygosity were identified. As the patients were from different
yet related Pennsylvania Amish demes, we suspected that the
shared homozygous block might be small and thus below the
resolution of a 10 K microarray. We subsequently genotyped these
patients at 50 K resolution and mapped the disease locus to
chromosome 7p22 (Figure 4, panel C).
In 2007, a microcephalic Mennonite baby was evaluated at the
CSC and thought to have the same disorder first described by
Victor McKusick in 1966 (microcephaly with chorioretinopathy, OMIM
251270) [30]. We were able to locate and genotype four affected
individuals from McKusick’s original study as well as another
patient related to our index case. Genotyping at 50 K SNP
resolution was required to identify a small 1.8 Mb shared block of
homozygosity in the subtelomeric region of chromosome 22q22
(Figure 4, panel D). For both disorders that required higher density
arrays, a dearth of SNPs on the 10 K microarray and high
recombination rates in these subtelomeric regions complicated
mapping.
Exome Sequencing
Prior to exome analysis, we sequenced between 2 and 45
candidate genes for each condition and found no pathogenic
variants. As defined here and throughout the paper, novelty of
DNA sequence variants was determined by absence in dbSNP 129
and the 1000 Genomes Project. All putative pathogenic exome
variants described below were confirmed by Sanger sequencing in
the affected individuals used for genetic mapping. In addition,
siblings and parents were also sequenced, when available, to
confirm appropriate segregation of the allele within the family. We
developed an unlabeled probe melting analysis for each putative
pathogenic variant and genotyped population-specific controls for
these variants. For each disorder, over 400 population-specific
chromosomes were screened, the allele frequencies ranged from 0–
1.25%, and no homozygous controls were identified. The exome
variant data are summarized in Tables 3 and 4.
Infantile Parkinsonism-dystonia syndrome. Exome
sequencing was performed on the single living patient. The data
were constrained by first tabulating all homozygous, novel
variants. Nineteen novel homozygous variants were identified: 8
synonymous, 9 missense, 1 59-UTR, and 1 splice site (Table 3). Of
the 10 potentially pathogenic changes, only one localized to a
region consistent with linkage in the family, SLC6A3 IVS9+1G.T.
The SLC6A3 gene encodes the dopamine transporter, a known
cause of infantile parkinsonism-dystonia syndrome (OMIM
613135). Direct sequencing revealed both parents were
heterozygous for this change, both affected individuals were
homozygous, and the unaffected siblings were either heterozygous
or homozygous wild-type. This confirmed the linkage block that
was identified on chromosome 5 by SNP genotyping. Genotyping
of 201 Old Order Mennonite control samples identified no
carriers (Table 4).
Lethal neonatal rigidity and multifocal seizure
syndrome. Exome data from two patients revealed nine
variants in the mapped interval, but only one, BRAT1
c.638_639insA, was novel (Table 3). Genotyping by unlabeled
probe melting analysis for 201 Old Order Amish control samples
identified 2 carriers (1.0%)(Table 4). Further confirmatory
evidence for the pathogenicity of this variant was provided by
two unrelated Old Order Amish infants from different demes in
Wisconsin and Kentucky who had an indistinguishable clinical
phenotype and were homozygous for the BRAT1 c.638_639insA
variant. Their samples were tested for the BRAT1 variant after
local physicians contacted our clinic for clinical guidance.
Microcephaly and chorioretinopathy. Exome data from a
single affected patient identified 15 sequence variants within the
mapped interval. Only one was novel, TUBGCP6 c.5458T.G
(Table 3). An unlabeled probe melting analysis in 202 Old Order
Mennonite control samples identified 4 carriers (2.0%)(Table 4).
This read-through variant is predicted to incorporate 16 extra
amino acids at the C-terminus of TUBGCP6 and/or may
accelerate mRNA degradation via non-stop mediated decay.
Non-syndromic mental retardation. Exome sequencing of
5 affected individuals identified 9 homozygous sequence variants
within the mapped interval. Only a missense variant in CRADD
(c.382G.C; p.Gly128Arg) was novel (Table 3). PolyPhen-2
predicted this change to be ‘‘probably damaging’’
(score=0.999). An unlabeled probe melting analysis detected 4
carriers among 203 Old Order Mennonite control individuals
(2.0%) (Table 4).
Posterior column ataxia and retinitis pigmentosa. Exome
data froma single AXPC1patient revealed23codingvariantsinthe
mapped interval; 13 were non-synonymous and only one missense
variant was novel, FLVCR1 c.361A.G (p.Asn121Asp) (Table 3).
PolyPhen-2 predicts the p.Asn121Asp change to be ‘‘probably
damaging’’ (score=0.997). An unlabeled probe melting analysis for
this variant detected 4 heterozygotes out of 203 Old Order
Mennonite control chromosomes (2.0%) (Table 4). The
pathogenicity of this variant and several others in FLVCR1 has
recently been confirmed independently by others [32].
Symptomatic epilepsy and skull dysplasia. Exome data
on three affected individuals from two sibships revealed 34
Table 4. Pathogenic Variant Summary.
Disease Sample Size Gene Gene Variant Protein Variant
Population-specific
Allele Frequency
Infantile parkinsonism-dystonia 1 SLC6A3 IVS9+1G.T – 0.0% (0/402)
Lethal neonatal rigidity and seizure
syndrome
3 BRAT1 c.638_639insA – 0.50% (2/402)
Mental retardation, non-syndromic 5 CRADD c.382G.C p.Gly128Arg 1.72% (7/406)
Microcephaly with chorioretinopathy 1 TUBGCP6 c.5458T.G p.Ter1820Gly 0.99% (4/404)
Posterior column ataxia with retinitis
pigmentosa
1 FLVCR1 c.361A.G p.Asn121Asp 1.23% (5/406)
Symptomatic epilepsy and skull dysplasia 3 SNIP1 c.1097A.G p.Glu366Gly 1.48% (6/406)
Usher syndrome 2 HARS c.1361A.C p.Tyr454Ser 1.72% (7/406)
doi:10.1371/journal.pone.0028936.t004
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e28936Figure 5. Overexpression of mouse Cradd in mIMCD3 cells. (A) Wild-type N-terminal FLAG-Cradd localizes to the cytoplasm and nucleus. (B)
Mutant N-terminal FLAG-Cradd (p.Gly128Arg) localizes to the cytoplasm and nucleus in a manner that is indistinguishable from the wild-type
localization. (C) Western blot of lysates from mIMCD3 cells transfected with wt FLAG-Cradd and wt V5-mPIDD, wt V5-mPIDD, or FLAG-Cradd
(p.Gly128Arg) and wt V5-mPIDD. Blot was labeled with anti-V5 monoclonal antibody. Note that full-length V5-mPIDD (110.5 kDa) was cleaved into a
57.1 kDa N-terminal fragment, suggesting normal autocatalytic activity. (D) Co-transfection of FLAG-Cradd (wt) and wt V5-PIDD death domain (DD)
results in uniform colocalization of the fusion proteins throughout the cytoplasm and nucleus (yellow). (E) Overexpressed V5-mPIDD DD (wt) localizes
to the cytoplasm and the nucleus. (F) Co-overexpression of FLAG-Cradd (p.Gly128Arg) with V5-mPIDD DD (wt) results in dense aggregations of FLAG-
Cradd in the cytoplasm. (G) Co-transfection of FLAG-mCradd (wt) and V5-mPIDD (wt) results in relatively uniform colocalization of the fusion proteins
throughout the cytoplasm (yellow); punctate FLAG-mCradd aggregation is also evident (green). FLAG-mCradd (wt) localizes to the nucleus (green),
V5-mPIDD does not (red). (H) Overexpressed V5-mPIDD (wt) localizes to the cytoplasm as previously reported (Berube et al., 2005). (I) Co-
overexpression of FLAG-mCradd (p. Gly128Arg) with V5-mPIDD (wt) results in dense aggregations of FLAG-mCradd in the cytoplasm, decreased
mCradd:mPIDD colocalization, and a relative loss of localization of mCradd to the nucleus. Green fluorescence – anti-FLAG M2 antibody (1:1000); Red
fluorescence – anti-V5 antibody (1:200); Blue fluorescence – DAPI-labeled nuclei (1.5 mg/ml); Western blots – anti-FLAG M2 antibody (1:1000). (J) Co-
immunoprecipitation (Co-IP) of V5-tagged mouse Pidd death domain (DD) with FLAG-tagged mouse Cradd DD in mIMCD3 cells. Wild-type FLAG-
Cradd DD co-immunoprecipitates wild-type Pidd DD; the FLAG-Cradd DD p.Gly128Arg variant does not. The upper blots were labeled with the anti-
FLAG M2 antibody (1:1000). The lower blots of the same lysates/eluates were labeled with the anti-V5 antibody (1:5000).
doi:10.1371/journal.pone.0028936.g005
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was novel, SNIP1 c.1097A.G (p.Glu366Gly) (Table 3). PolyPhen-
2 predicts the p.Glu366Gly substitution to be ‘‘probably
damaging’’ (score=0.99). An unlabeled probe melting analysis
for this variant identified 5 carriers among 203 Old Order Amish
controls (2.5%) (Table 4).
Usher syndrome. Exome data from two patients revealed 80
homozygous variants within the mapped interval. Only one
variant, HARS c.1361A.C (p.Tyr454Ser), was novel (Table 3).
Unlabeled probe melting analysis detected 3 carriers among 203
Old Order Amish controls (1.5%) (Table 4). Further evidence for
pathogenicity was provided by an Old Order Amish patient who
was from an unrelated deme in Ontario, Canada. This Amish
settlement arose from a separate migrational event from Europe
than the Lancaster County settlement. The patient had an
identical phenotype to our patients and was homozygous for the
HARS c.1361A.C variant.
In vitro Studies
The BRAT1 gene encodes BRCA1-associated protein required
for ATM activation-1 (BRAT1) [33]. Wild-type human BRAT1
displays prominent nuclear and diffuse cytosolic localization
(Figure 1, D) and its C-terminus (amino acids 176–821) interacts
with BRCA1 [33]. The c.638_639insA change is a frameshift
variant that is predicted to alter the amino acid sequence after
Lys
213 by introducing a stop codon that prematurely truncates the
protein at Leu401 (41.5 kDa vs. wild-type 88.1 kDa) (Figure 1, F),
abolishes its nuclear localization, and renders the protein unstable
in human ARPE-19 cells (Figure 1, E–G). Similar results were
obtained with mouse BRAT1 (data not shown). Abundance of the
c.638_639insA variant was 87.7611.9% (n=3) lower than that of
wild-type human BRAT1 for FLAG-fusion proteins overexpressed
in human ARPE-19 cells (Figure 1, G). These data suggest that the
Amish variant destabilizes the protein and may disrupt an
interaction between BRAT1 and BRCA1 that is required for
nuclear localization of BRAT1. Knockdown of BRAT1 results in
p53-induced apoptosis independent of DNA damage [33]. The
destabilization of BRAT1 observed might underlie the catastroph-
ic epilepsy and corticobasal neuronal degeneration observed in
affected infants [34,35,36,37,38].
CRADD. CRADD (aka RAIDD) is a caspase-recruitment-
domain (CARD) and death domain containing adaptor protein. It
links PIDD (p53-induced protein with death domain) and caspase-
2 in the formation of the PIDDosome required for caspase-2
activation during apoptosis [39,40,41,42].
The CRADD c.382G.C mutation alters a highly conserved
residue (p.Gly128Arg) within the CRADD death domain. We
overexpressed wild-type and mutant (p.Gly128Arg) murine Cradd
in mouse inner medullary collecting duct cells (mIMCD3) and
found no significant difference in protein localization (Figure 5, A–
B) [43]. However, mutant p.Gly128Arg Cradd formed large
aggregates when co-overexpressed with wild-type PIDD (Figure 5,
I) or the PIDD death domain (Figure 5, F). We found that
overexpressed PIDD localized to cytosol (Figure 5, H) as described
previously [43] and was autocatalytically cleaved as expected
(Figure 5, C) [42]. These data suggest that the p.Gly128Arg
mutation alters one of the interaction surfaces of the CRADD
death domain to decrease affinity for the PIDD death domain and
increase homotypic binding to the CRADD death domain [44].
This is further supported by co-immunoprecipitation assays
demonstrating that wild-type Cradd DD co-immunoprecipitates
Pidd DD, but Cradd DD p.Gly128Arg does not (Figure 5, J). In
rat PC-12 cells and cultured sympathetic neurons, similar
perinuclear Cradd aggregations are associated with caspase-2
activation and initiation of apoptosis [45]. In humans, alteration of
caspase-2 initiated apoptosis (resulting from disruption of the
PIDDosome) during nerve growth factor mediated proliferation of
synaptic contacts may lead to inappropriate synaptic pruning that
results in cognitive impairment.
SNIP1. Wild-type SNIP1 (Smad nuclear interacting protein 1)
contains an N-terminal nuclear localization signal [46], bridges c-
Myc activity with CBP/p300 activity during development, and
competitively inhibits TGF-b and NF-kB signaling [47,48]. SNIP1
Glu
366 is highly conserved and the p.Glu366Gly mutation is in the
C-terminus where SNIP1 interacts with c-Myc [48], Smad1 and
Smad2 [46,49].
Reverse transcriptase-PCR suggests that the Snip1 c.1058A.G
(corresponding to human SNIP1 c.1097A.G) transcript is
expressed at levels comparable to wild-type (Figure 3, F). We
transiently overexpressed wild-type and mutant Snip1 in
mIMCD3 cells. Wild-type protein localized to the nucleus with a
punctate appearance, consistent with its involvement in transcrip-
tional complexes [46,48] (Figure 3, D). However, Snip1
p.Glu353Gly (corresponding to human p.Glu366Gly) had a more
aggregated appearance (Figure 3, E) and Western blotting proved
it unstable (Figure 3, F); its band density was 84.969.6% SD lower
than wild-type (n=4 independent transfections each).
Decreased abundance of SNIP1 likely results in decreased c-
Myc activity and increased TGF-b and NF-kB signaling.
Disruption of c-Myc or CBP/p300 signaling in mice can result
in abnormal development of the brain, skull, craniofacial bones,
and distal limbs [50,51,52,53,54]. Inappropriate increases in TGF-
b/Smad2 signaling and in NF-kB signaling in the mouse brain
have been shown to independently initiate epileptogenesis [55,56].
HARS. Histidyl-tRNA synthetase (HARS/HisRS) is a
homodimeric class IIa aminoacyl tRNA synthetase that charges
tRNA with the amino acid histidine [57]. The p.Tyr454Ser
change rests in the interface between the catalytic domain and
anticodon binding domain suggesting that it may alter anticodon
recognition and/or catalytic activity. Overexpression of wild-type
and mutant (p.Tyr454Ser) murine HARS in mIMCD3 cells did
not reveal any significant differences in localization (Figure 6, A–
B). In Chinese hamster ovary (CHO) cell lysates, both wild-type
and mutant murine protein dimerized properly with endogenous
HARS and were expressed at qualitatively similar levels (data not
shown). Our data suggest that the p.Tyr454Ser change reduces the
maximal forward reaction velocity (Vmax) of the enzyme for
aminoacylation of human tRNAHis with histidine nearly two-fold
(Figure 6, C).
Discussion
Next generation sequencing technologies promise to expedite
disease gene discovery and allowed us to identify known and novel
pathogenic variants in our patients. Although costly, exome
sequencing is practical as it interrogates the 1.5% of the genome
that contains approximately 95% of pathogenic variants
[12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28]. To assess
the utility of exome sequencing in an active clinical setting, we
selected 15 patient samples representing 7 different genetic
conditions. Each disorder had previously been mapped to a
chromosomal locus and candidate gene sequencing failed to
identify the pathogenic variant. For six disorders, an average
autozygous block of 4.4 Mb (0.13% of the human genome)
contained only one novel homozygous variant and rendered
disease gene identification straightforward. Even in the case of
infantile parkinsonism-dystonia syndrome, for which autozygosity
and linkage mapping were only partially informative, a manage-
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assuming mutation homogeneity. Prior mapping data and
thorough knowledge of the patient implicated a single variant
from this list (SLC6A3 IVS9+1G.T).
For four of the conditions, more than one affected individual
was available for exome sequencing. Even in the absence of
mapping data, the identification of the putative pathogenic variant
would still have been unambiguous. When we examined the
shared, novel homozygous variants in affected individuals, we
found one, and only one, that was not homozygous in any other
(unaffected) individuals in the study. Thus, the assumption of
mutation homogeneity obviates the need for SNP genotyping and
mapping; we reach the same conclusion by exome sequencing of
multiple affected individuals without the added time and expense
of SNP genotyping.
The number of novel homozygous variants in each individual
was surprisingly small. Average inbreeding coefficients of 4% and
2.5% in the Lancaster Amish and Mennonite populations,
respectively, suggested that a small but significant fraction of
variation will be homozygous. On average, we found only 21 novel
homozygous variants per sample across the exome. Of these
variants, only 12 were predicted to be potentially pathogenic
(missense, nonsense, splice site). This represents 3.7% of all novel
variants per exome. For the two disorders where a singleton was
sequenced, we identified only 6 potentially pathogenic novel
variants which were homozygous in the patient but in no other
Figure 6. Overexpression of mouse HARS in mIMCD3 cells. (A) Wild-type N-terminal FLAG-HARS localizes to the cytoplasm. (B) Mutant N-
terminal FLAG-HARS (p.Tyr454Ser) localizes to the cytoplasm in a manner that is indistinguishable from the wild-type localization shown in A.
Transfected and non-transfected cells were labeled with anti-FLAG M2 monoclonal antibody and AlexaFluor 488-conjugated anti-mouse IgG1 (green
fluorescence). (C) Reaction velocity vs. human tRNA
His concentration for histidine aminoacylation of tRNA
His by wild-type murine HARS (HARS) and
p.Tyr454Ser (Y454S) HARS. Scale bar=10 mmi nA and B.
doi:10.1371/journal.pone.0028936.g006
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expect that future studies which leverage accumulated exome data
will allow us to sequence single individuals to identify rare,
uniquely homozygous pathogenic variants. In the outbred
population, a strategy that scans for homozygosity or compound
heterozygosity for novel variants in the same gene should yield
equally manageable candidate gene lists.
Among the fifteen individuals studied, we found 4200 different
novel autosomal sequence variants, roughly 62% of which have
pathogenic potential. We infer that 3.6% of these variants were
non-pathogenic changes as they were homozygous in one or more
unaffected individuals. As more Amish and Mennonite exomes are
analyzed within a clear clinical context, our ability to determine
pathogenicity will improve. The exome data also provided a
broader view of the genetic disease burden within these
populations. We have catalogued 94 known pathogenic sequence
variants within the Plain populations that should be detectable by
exome sequencing. Of these, 11 were represented in at least one
individual. On average, each individual harbored 1.4 known Plain
pathogenic alleles (range, 0–4). We also compared our exome
results against the Human Gene Mutation Database (HGMD)
[58]. Carrier status for 113 HGMD mutations, that cause
phenotypes not yet encountered in the Plain populations, was
detected in our patients. These data permit us to generate a more
comprehensive molecular differential diagnosis list when faced
with a new clinical phenotype. It is notable that several HGMD-
DM mutations were homozygous in one or more patients, casting
some doubt on the pathogenicity of these variants. Similar results
have been reported elsewhere and highlight the need for better
curation of mutation databases [59].
Critics will argue that we have failed to exclude all possible
variants due to incomplete coverage. Our sequencing metrics show
excellent, albeit incomplete, exome coverage. On average, 91.8%
and 86.6% of the targeted exome was sequenced to a depth of 106
and 206, respectively. While this is a potential hazard, our study
design minimized this risk. Prior mapping analyses narrowed the
focus to a vanishingly small 0.13% of the genome. Within these
mapped regions, we discovered only one novel homozygous
variant. This is significantly better coverage and stronger evidence
than we and others have demonstrated for disease gene
identification prior to the advent of exome sequencing. Addition-
ally, our SNP filtering strategies might be questioned; dbSNP is
polluted with many pathogenic variants and their numbers
continue to grow as data accrues. Our current conservative
strategy used dbSNP 129 and the 1000 Genomes Project to filter
exome variants. The risk to our analyses is relatively small since we
study very rare and highly penetrant alleles. Nonetheless, in our
population and elsewhere, local population-specific variant
databases will prove most useful for inferring pathogenicity.
Pathogenicity is difficult to prove, but for four conditions we
provide ample functional data to demonstrate abrogation of
protein function. In vitro studies of protein localization and
function in mammalian cells provide further confirmation that the
homozygous variants identified were indeed pathogenic. The
predicted consequence of the BRAT1 c.638_639insA frameshift
variant is a truncated protein at amino acid position 401.
Overexpression of this truncated protein abolished nuclear
localization and demonstrated protein instability (87.7% decrease
relative to wild-type). An alternative disease mechanism, nonsense-
mediated mRNA decay, has not been investigated. Others have
shown that knockdown of BRAT1 results in p53-induced
apoptosis [33]. This is consistent with the neurodegeneration
observed in patients with the BRAT1 variant. When transfected
into mouse IMCD3 cells, the mouse counterpart of the CRADD
c.382G.C variant disrupts interaction with mouse Pidd (it’s
normal binding partner) and forms dense aggregates when co-
expressed with wild-type mouse Pidd. This is in contrast to a
pattern of uniform colocalization of wild-type Cradd and Pidd
throughout the cytoplasm and nucleus. Mouse Snip1 protein,
when transiently overexpressed in IMCD3 cells, localizes to the
nucleus in a punctate pattern consistent with transcriptional
complexes, while mutant mouse Snip1 (p.Glu353Gly, correspond-
ing to human p.Glu366Gly) localizes to the nucleus, but with a
more aggregated distribution. Western blotting proved this
structure unstable. For the HARS c.1361A.C variant, we
demonstrate that reaction velocity (Vmax) for aminoacylation of
human tRNAHis with histidine is reduced nearly two-fold. While
these studies cannot prove pathogenicity beyond a shadow of
doubt, the totality of evidence is compelling and strongly suggests
that we have identified the disease-causing alleles. The association
between FLVCR1 and SLC6A3 variants and disease has previously
been established.
We provide no further evidence for pathogenicity of the
TUBGCP6 c.5458T.G variant. However, the primary micro-
cephalies result from disruption of the centrosomal complex
during mitosis, reducing the neural progenitor pool during
development (39–41). Centrosomal proteins such as CDK5RAP2
and CENPJ/CPAP interact with the c-tubulin ring complex (c-
TuRC) to regulate microtubule nucleation (42–44). TubGCP6
(GCP6) is a component of the human c-TuRC (45), where it is
required for CDK5RAP2 to activate microtubule nucleation (43).
We predict that defects in TUBGCP6, CDK5RAP2 and CENPJ
cause primary microcephaly by similar mechanisms.
All seven variants described in this paper interfere with
neurological development. Functional studies of BRAT1 and
SNIP1 will expand our understanding of epilepsy and also deepen
our knowledge of DNA damage repair and transcriptional
regulation in cortical development and neuronal survival. Selective
degeneration of photoreceptors and dorsal column afferents
caused by FLVCR1 mutations suggest an unusual vulnerability of
these cells to deranged heme transport, or may reveal an
altogether different function of the FLVCR1 protein. Despite its
ubiquitous expression, a defect in aminoacylation by HARS
selectively damages elements of afferent sensory systems and, by
unknown mechanisms, predisposes to episodic psychosis and
sudden death. Abnormalities of neuroblast proliferation and
migration caused by TUBGCP6 mutations fit nicely with our
existing knowledge about centrosomal complexes, microtubular
arrays, and cortical growth, but also introduce new questions
about the diverse brain morphologies linked to various specific
tubulin-associated proteins and the role of these proteins in early
eye development. Finally, further studies on the connection
between CRADD and general intelligence will certainly change
our understanding of the microanatomical and molecular bases of
cognition. Small focused studies as described herein will be a
steady engine of progress for understanding the specific connec-
tions between genes and the human brain.
Ultimately, genomics can only shape medical practice within the
context of regional particulars and clinical facts. Our local, patient-
and family-based approach to gene discovery stands in stark
contrast to the prevailing model of genomic research, where the
people who produce genotype data are frequently separated from
those who collect and analyze clinical facts, and both struggle to
translate genetic knowledge into primary care. Although we are
focused on specific regional populations (1, 3), these studies reveal
concepts of broad biological and economic relevance (8, 11). The
discovery of rare, highly penetrant alleles among small social groups
may prove more useful than large genome-wide association studies
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particularly when these alleles can be viewed against a background
of population-specific genetic variation. Even at current prices,
microarray analyses to detect copy number abnormalities coupled
with exome sequencing are an order of magnitude cheaper than the
standard workup for a complex patient at a tertiary medical center.
Thoughtful and appropriately scaled application of these genetic
technologies to other regional populations should yield similar
economic and clinical benefits in the years ahead.
Materials and Methods
The study was approved by Institutional Review Boards at
Lancaster General Hospital and the Broad Institute. All parents
consented to participation. Patients were from Old Order Amish
or Mennonite populations, received medical care at the Clinic for
Special Children (CSC), and presented with a distinctive recessive
clinical phenotype (Table 1).
Genetic Mapping
Genetic mapping of the seven disorders presented in this study
was performed as previously described [5,6,7,8,9,10,11] with the
exception that two disorders required higher density arrays
(Affymetrix 50 K) to establish chromosomal location. Single-
nucleotide polymorphism (SNP) genotyping was performed with
the GeneChip Mapping 10 K and 50 K Assay Kits (Affymetrix,
Santa Clara,CA,USA) aspreviouslydescribed.Data wereanalyzed
in Microsoft Excel spreadsheets (Microsoft Corporation, Redmond,
WA, USA) that were custom formatted at the Clinic for Special
Children. SNP positions came from Affymetrix genome annotation
files and genotype data came from the Affymetrix GeneChip
Human Mapping 10 K Xba 142 and 50 K Xba Arrays. Data
analyses were designed for rapid identification of genomic regions
that were identically homozygous between all affected individuals.
These analyses assumed mutation and locus homogeneity. Two-
point lod scores were calculated for each genotyped SNP using an
approachsimilartoBromanand Weber[60].Cumulativetwo-point
lod scores for blocks of homozygous SNPs were considered the
location score for that region, providing a relative measure that a
specific homozygous block harbored the disease gene. Genotype
data from 100 healthy population-specific (Amish or Mennonite)
females were used for estimation of SNP allele frequencies.
Exome Sequencing
Exome sequencing was performed using the Agilent SureSelect
All Exon Kit (v.1, 38 Mb) as previously described [61]. A solution
hybrid selection methodology was used to isolate exomic DNA,
which was subjected to sequencing on the Illumina GA-II
platform. Briefly, DNA oligonucleotides, corresponding to
120 bp of target sequence flanked by 15 bp of universal primer
sequence, were synthesized in parallel on an Agilent microarray,
then cleaved from the array. The oligonucleotides were PCR
amplified, then transcribed in vitro in the presence of biotinylated
UTP to generate single-stranded RNA ‘‘bait.’’ Genomic DNA was
sheared, ligated to Illumina sequencing adapters, and selected for
lengths between 200–350 bp. This ‘‘pond’’ of DNA was
hybridized with an excess of bait in solution. The ‘‘catch’’ was
pulled down by magnetic beads coated with streptavidin, then
eluted, and sequenced on the Illumina GA-II.
Massively parallel sequencing data were processed by the
Sequencing Platform at the Broad Institute using two consecutive
pipelines. The first pipeline, called ‘‘Picard’’, utilized the reads and
qualities produced by the Illumina software for all lanes and
libraries and produced a single BAM file (http://samtools.
sourceforge.net/SAM1.pdf) representing a sample. The final
BAM file stored all reads with well-calibrated qualities and
alignments to the genome. The second pipeline, called Genome
Sequencing Analysis, then performed post-processing and analysis
of the data including SNP identification, small insertion and
deletion identification, local realignment of insertion or deletion
containing reads, gene annotation and filtering with common
polymorphisms (1000 Genomes, dbSNP build 129). The details of
our sequencing data processing have been described elsewhere
[62]. Inter-exome analyses were performed by importing variant
call data into a FileMaker Pro database (FileMaker, Inc., Santa
Clara, CA) and querying mapped intervals for novel variants
shared among affected individuals.
Candidate Disease Gene Cloning
Total RNA extracted with Trizol (Invitrogen, Carlsbad, CA)
from wild-type mouse tissues, cultured mouse IMCD3 cells, or
human ARPE19 cells was reverse transcribed with SuperScript II
reverse transcriptase (Invitrogen). Gene specific primers were used
to amplify full-length cDNA (coding sequence, CDS) for the
candidate disease genes by the polymerase chain reaction (PCR).
Mouse PIDD was amplified from pcDNA3.1(2)/mPIDD (a gift
from S. Benchimol, York University, Toronto, Ontario, Canada).
Constructs were ligated into D-TOPO Gateway entry vectors
(Invitrogen) for cloning, and site-directed mutagenesis (Quik-
Change II, Agilent, Santa Clara, CA) was used to introduce the
mutations discovered by exome sequencing. Wild-type and mutant
constructs (confirmed by Sanger sequencing of the full-length
inserts) were subcloned into pCAG/FLAG/RFC/A and/or
pCAG/V5/RFC/A (gift of Q. Zhang and E.A. Pierce, University
of Pennsylvania, Philadelphia, PA) for expression of N-terminal
FLAG- and/or V5-fusion proteins in mammalian cells.
Immunohistochemistry
For protein localization studies, mIMCD3 cells grown to 80–
90% confluence on glass coverslips in six-well plates were
transfected with FLAG and/or V5-fusion protein expression
vector plasmid DNA using Lipofectamine 2000 (Invitrogen). Cells
were grown for 40–48 h post-transfection and then fixed for
10 min in 4% paraformaldehyde in phosphate buffered saline
(PBS), permeabilized for 10 min with 0.5% Triton X-100 in PBS,
blocked for 10 min with 1% bovine serum albumin in PBS with
0.2% Triton X-100, and incubated with primary antibodies for
1 h at room temperature (RT). Following a wash in PBS, cells
were incubated in secondary antibodies for 1 h at RT. Nuclei were
counterstained with DAPI (49,6-diamidino-2-phenylindole –
1.5 mg/ml; Santa Cruz Biotechnology, Santa Cruz, CA) and
coverslips were mounted with Fluoromount G (Electron Micros-
copy Sciences, Ft. Washington, PA). Fluorescent images were
captured with a Leica DM RB microscope. Primary antibodies –
monoclonal anti-FLAG M2 IgG1 (1:1000; Sigma, St. Louis, MO)
and/or monoclonal anti-V5 IgG2a (1:200; Invitrogen). Secondary
antibodies – DyLight 488-conjugated goat anti-mouse IgG (1:400;
Jackson ImmunoResearch, West Grove, PA), AlexaFluor 488-
conjugated goat anti-mouse IgG1 (1:400), and/or AlexaFluor 594-
conjugated goat anti-mouse IgG2a (1:400; Invitrogen).
Western Blotting, Co-immunoprecipitation, and RT-PCR
Western blotting was used to assess relative protein overexpres-
sion levels. Briefly, 100% confluent mIMCD3 cells in six-well or
10-cm plates transfected as described above were lysed in either
46LDS sample buffer (Invitrogen) or in lysis buffer (CelLyticM,
Sigma) containing protease inhibitor and phosphatase inhibitor
cocktails (Roche Applied Science, Indianapolis, IN). Lysates were
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10–15 min. Following SDS-PAGE, proteins were blotted to
nitrocellulose, and the membranes were blocked for 1 h at RT
with 5% nonfat dry milk in Tris buffered saline (TBS) with 0.1%
Tween-20. Membranes were then incubated with primary
antibody (anti-FLAG M2 – 1:1000 or anti-V5 – 1:5000) overnight
at 4uC, washed in TBS with 0.1% Tween-20, and then incubated
with secondary antibodies for 1 h at RT. Secondary antibodies –
horseradish peroxidase (HRP)- conjugated goat anti-mouse IgG
(1:1500) and HRP-conjugated anti-biotin (1:1000). Proteins were
detected with enhanced chemiluminescence using LumiGLO (Cell
Signaling Technology, Danvers, MA) and chemiluminescence
signals were imaged on BioMax Light film (Kodak, Rochester,
NY). Band densities were measured with ImageJ (http://rsbweb.
nih.gov/ij/) following calibration with a NIST calibrated step
tablet (Kodak EK1523406).
Co-immunoprecipitation was carried out using the FLAG-M2
affinity resin according to the manufacturer’s protocols (Sigma
CELLMM2/F2426) with the following exception: cleared lysates
were incubated at 37uC for 1 h prior to overnight incubation on
the resin.
Reverse transcriptase-PCR was used to assess relative transcript
levels for genes overexpressed in cultured mIMCD3 cells. Cells
were transfected on 10-cm plates and cultured as described above.
Total RNA was harvested, incubated with DNase (1 U/mg RNA)
at 37uC for 30 min, and reverse transcribed as described above. A
FLAG-tag specific forward primer and gene specific reverse
primers were used to determine the transcript levels for the
overexpressed gene relative to endogenous GAPDH or b-actin
expression using 20–24 cycles of PCR. Total transcript levels
(endogenous+overexpressed) for the gene of interest were deter-
mined with gene specific primer pairs for short (300–500 bp)
amplicons relative to GAPDH expression.
Aminoacylation assays
Murine HARS and the variant p.Tyr454Ser HARS were
expressed in Chinese hamster ovary (CHO) cells as FLAG-tagged
enzymes and affinity purified. Enzymes were stored at 220uCi n
34 mM Tris HCl, pH 7.4, 100 mM NaCl, 50% glycerol at a
concentration of 10 mM and diluted to 1 mM in cold reaction
buffer (50 mM HEPES pH 7.5, 100 mM KCl, 10 mM MgCl2
and 1 mM DTT) just before use. Human tRNAHis, which has an
identical sequence to murine tRNAHis, was prepared from human
placenta as described, with minor modifications [63]. Isolated
placental RNA was stored at 220uC in 10 mM Na Cacodylate
(pH 6.0). This preparation yields approximately 25 mg RNA/g
tissue, of which 1.4% (22.4 pmol/A260 unit) can be aminoacy-
lated with histidine by murine HARS.
Kinetics assay
Enzyme assays were performed under steady state conditions for
ATP and histidine, with the concentration of tRNA varied from
approximately 0.2 to 56 KM, as previously described [64,65].
Briefly, ATP (2.5 mM), [3H] histidine mixed with histidine
(25 mM, 19% radiolabeled), pyrophosphatase (10 ng/ml) and
buffer (50 mM HEPES pH 7.5, 100 mM KCl, 10 mM MgCl2
and 1 mM DTT) were mixed with placental tRNA (35.9 to
402 mM, of which 1.4% could be histidylated). The reaction was
initiated by addition of enzyme (100 nM), and quenched by
spotting on filter paper pre-soaked with 10% trichloroacetic acid.
After washing away unbound radiolabeled histidine, the histidy-
lated tRNA was quantified by scintillation counting. The time
course reactions were analyzed using KinTek Explorer software,
yielding a velocity versus substrate curve from which kinetic
parameters were determined.
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